iCAD (NASDAQ:ICAD) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Thursday.

iCAD (NASDAQ ICAD) traded up $0.44 during mid-day trading on Thursday, reaching $4.00. 78,021 shares of the company traded hands, compared to its average volume of 61,067. iCAD has a fifty-two week low of $3.13 and a fifty-two week high of $6.07. The firm has a market capitalization of $57.29, a price-to-earnings ratio of -4.94 and a beta of 1.54. The company has a current ratio of 1.95, a quick ratio of 1.67 and a debt-to-equity ratio of 0.31.

iCAD (NASDAQ:ICAD) last released its earnings results on Wednesday, November 8th. The technology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. iCAD had a negative net margin of 49.16% and a negative return on equity of 47.31%. The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.43 million. equities analysts forecast that iCAD will post -0.62 earnings per share for the current year.

Several large investors have recently modified their holdings of ICAD. Argent Capital Management LLC lifted its position in shares of iCAD by 13.2% in the 2nd quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock valued at $2,990,000 after acquiring an additional 82,967 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of iCAD by 165.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 89,043 shares of the technology company’s stock valued at $394,000 after acquiring an additional 55,455 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of iCAD in the 3rd quarter valued at approximately $133,000. Finally, Vanguard Group Inc. lifted its position in shares of iCAD by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock valued at $1,912,000 after acquiring an additional 2,007 shares in the last quarter. Institutional investors and hedge funds own 21.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/04/icad-icad-upgraded-at-valuengine.html.

About iCAD

iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.